人才队伍

张定校

时间:2021年08月23日 20:12 点击: 字体大小:

基本情况

湖南大学,生命医学交叉研究院,教授, 博士生导师,湖南省杰出青年科学基金项目获得者,岳麓学者。E-mail: zdx1980@hnu.edu.cn


教育经历

2006.09 – 2010.02 韩国忠北国立大学,分子胚胎发育学,博士

2003.09 – 2006.06 华中农业大学,分子生物学,硕士

1999.09 – 2003.06 华中农业大学,动物科学,本科


工作经历

2019.07 – 至今 湖南大学,生命医学交叉研究院,教授

2018.09 – 2019.07 华中农业大学,生物医学中心,教授

2016.09 – 2018.12 美国Roswell Park Cancer Center,助理教授 (Assistant Professor of Oncology)

2016.06 – 2016.09 美国Roswell Park Cancer Center,青年研究员 (Affiliate Member)

2015.04 – 2016.05 美国MD Anderson Cancer Center,讲师 (Instructor)

2012.02 – 2015.03 美国MD Anderson Cancer Center,博士后

2010.04 – 2012.02 美国University of Cincinnati College of Medicine,博士后


研究成果简介

主要从事前列腺癌,乳腺癌,癌症干细胞和靶向药物治疗等研究。目前总共发表SCI论文近30篇,近5年研究成果主要发表在Nature子刊Nature Communications (2020, 2018, 2017, 2016) Cell子刊Trends in Cancer (2018), Stem Cell Reports (2018), 以及其他Top期刊Journal of Hematology & Oncology (2021), Seminar in Cancer Biology (2018), Cellular and Molecular Life Sciences (2020), EBioMedicine (2018), Stem Cells Translational Medicine (2017), Clinical Cancer Research (2016), Cell Discovery (2016) 等国际杂志上。回国前主持美国NIH/NCI-R21基金一项。目前主持国自然-面上,湖北省前沿科技-生物医学专项,和湖南省杰出青年基金各一项。目前担任 Nature Communications, Seminar in Cancer Biology, Cell Reports, Stem Cells, Cancer Communications, Cancer Letters, Molecular Carcinogenesis, Journal of Cellular and Molecular Medicine等多家国际期刊审稿人。


研究领域

以性激素敏感型癌症 (主要是前列腺癌和乳腺癌) 为模型,研究癌症发生、发展以及药物治疗抵抗的机理,寻找潜在新的癌症治疗靶点和临床治疗方案。目前研究方向有:癌症功能基因组学 (结合临床样本和生物组学大数据), 癌症干细胞的维持和分化,CRISPR功能基因组筛选,和癌症 (干细胞) 的治疗。目前已经有1项成果在美国开展临床I期,另外一项成果正在积极向临床I期推进。


科研项目

1. 2018-2020NIH/NCI – R21前列腺癌干细胞与临床治疗, $47.2万,主持

2. 2019-2021,武汉市前资助科技计划项目生物医学专项, 50, 主持

3. 2020-2023,国家自然科学基金-面上项目,55万,主持

4. 2021-2023,湖南省杰出青年基金,50万,主持

5. 2019-2025,湖南大学,高层次人才启动基金,主持


代表论文(*为通讯作者,IF2021年最新影响因子)

1. Zou C., He Q., He L., Feng YQ., Chen MJ., Zhang D*. A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR Cancer, 2022 https://doi.org/10.1093/narcan/zcac010.

2. Xiong JL, Yan LL, Zou C, Wang K, Chen M, Xu B, Zhou ZZ, Zhang D*. Integrins Regulate Stemness in Solid Tumor: An Emerging Therapeutic Target. Journal of Hematology & Oncology (IF=23.168), 2021, 14(1):177.

3. Zou C., Wan Y., He L., Zheng J., Mei Y., Shi J., Zhang M., Dong Z., Zhang D*. RBM38 in Cancer: Role and Mechanism. Cellular and Molecular Life Sciences (IF=9.207), 2021 doi: 10.1007/s00018-020-03593-w.

4. Zhang D,* Hu Q., Li XY., Kirk J., Tang DG*. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature Communications (IF=17.694), 2020 11(1):2089.

5. Zhao C, Xie S, Wu H, Luan Y, Hu S, Ni J, Lin R, Zhao S, Zhang D*, Li X*. Quantification of allelic differential expression using a simple Fluorescence primer PCR-RFLP-based method. Scientific Reports (IF=4.99) 2019 Apr 19;9(1):6334

6. Zhang D,* Zhao SH., Li XY., Kirk J., Tang DG*. Prostate Luminal Progenitors in Development and Cancer. Trends in Cancer  (IF=19.161), 2018, 4(11):769-783.

7. Zhang D*, Tang DG. "Splice" a way towards neuroendocrine prostate cancer. EBioMedicine (IF=11.205) 2018, pii: S2352-3964(18)30331-1.

8. Zhang D,* Tang DG* and Rycaj K*. Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Seminars in Cancer Biology (IF=17.012), 2018, (17)30280-8

9. Zhang D*, Gong S., Lu Y., Jeter C., Tang DG*. Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration. Stem Cell Reports (IF=7.294), 2018, 10(1):228–242.

10. Zhang D*, Lin, K., Lu, Y., Rycaj, K., Zhong, Y., Chao, H.P., Davis, T., Shen, J., and Tang, D.G*. Developing a novel 2D culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate cancer. Stem Cells Translational Medicine (IF=7.655), 2017, 6(3): 748-760.

11. Zhang D*, Park, D., Zhong, Y., Lu, Y., Gong, S., Chen, X., Liu, X., Chao, H.P., Whitney, P., Davis, T., Takata, Y., Shen, J., Iyer, V.R., Tang, D.G*. Stem cell and neurogenic gene expression profiles link prostate basal cells to aggressive prostate cancer. Nature Communications (IF=17.694), 2016, 7:10798.

12. Liu C#., Liu R#., Zhang D., Deng Q., Liu B., Chao HP., Rycaj K., Takata Y., Lin K., Lu Y., Zhong Y., Krolewski J., Shen J., and Tang D*. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications (IF=17.694), 2017, 8:14270.

13. Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, Jeter C, Rycaj K, Calhoun-Davis T, Huang J, Rubin MA, Beltran H, Shen J, Chatta G, Puzanov I, Mohler JL, Wang J, Zhao R, Kirk J, Chen X, Tang DG. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature Communications (IF=17.694). 2018;9(1):3600.

14. Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, Zhang D, Liu B, Jeter C, Calhoun-Davis T, Lin K, Lu Y, Chao HP, Shen J, Tang DG. Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clinical Cancer Research (IF=13.801), 2016, 22(17): 4505-16.

15. Jeter C, Liu B, Lu Y, Chao HP, Zhang D, Liu X, Chen X, Li Q, Rycaj K, Davis T, Yan L, Hu Q, Wang J, Shen J, Liu S, and Tang DG. NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discovery (IF=38.079), 2016, 2,16041.

更多论文发表链接NCBIhttps://www.ncbi.nlm.nih.gov/myncbi/1r9DwycZd6wA_/bibliography/public/